Drugs / Garlic powder standardized to allicin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06833125 | Mar 2025 → Mar 2026 overdue | nosocomial infection | Alexandria University | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Garlic powder standardized to allicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06833125 ↗ |
| Known as | Tomex plus | “The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial...” NCT06833125 ↗ |